Viewing Study NCT06991556

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:16 PM
Ignite Modification Date: 2026-02-03 @ 2:10 AM
Study NCT ID: NCT06991556
Status: RECRUITING
Last Update Posted: 2025-12-08
First Post: 2025-05-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Hormone-sensitive Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Interventional View
None clinical trial View
None open-label View
None JSB462 View
None luxdegalutamide View
None efficacy View
None safety View
None tolerability View
None abiraterone View
None metastatic hormone-sensitive prostate cancer View